Galectin Therapeutics Inc. (GALT) financial statements (2021 and earlier)

Company profile

Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments274783152629
Cash and cash equivalents274783152629
Other undisclosed current assets2111011
Total current assets:294894162630
Noncurrent Assets
Property, plant and equipment      0
Intangible assets, net (including goodwill)    000
Intangible assets, net (excluding goodwill)    000
Other noncurrent assets0000   
Total noncurrent assets:0000000
TOTAL ASSETS:304894162630
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1223412
Accounts payable1201101
Accrued liabilities  22311
Employee-related liabilities      1
Interest and dividends payable0000000
Other undisclosed current liabilities41    (1)
Total current liabilities:5323412
Noncurrent Liabilities
Liabilities, other than long-term debt00     
Other liabilities00     
Total noncurrent liabilities:00     
Total liabilities:5323412
Stockholders' equity
Stockholders' equity attributable to parent, including:22445(1)101821
Preferred stock     11
Common stock0000000
Additional paid in capital262260194173167158140
Accumulated deficit(240)(216)(196)(181)(164)(140)(119)
Other undisclosed stockholders' equity attributable to parent11777  
Other undisclosed stockholders' equity2222277
Total stockholders' equity:244671122528
TOTAL LIABILITIES AND EQUITY:304894162630

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(23)(13)(14)(16)(21)(20)(15)
Operating loss:(23)(13)(14)(16)(21)(20)(15)
Nonoperating income (expense)(0)0(0)000(0)
Investment income, nonoperating0000000
Interest and debt expense(0)(0)(0)(0)   
Loss from continuing operations before equity method investments, income taxes:(24)(13)(14)(16)(21)(20)(16)
Loss from equity method investments      (0)
Net loss:(24)(13)(14)(16)(21)(20)(16)
Other undisclosed net income attributable to parent0000  0
Net loss attributable to parent:(23)(13)(14)(16)(21)(20)(16)
Preferred stock dividends and other adjustments(0)(0)(1)(1)(1)(1)(1)
Other undisclosed net loss available to common stockholders, basic (7)  (0)(0)(0)
Net loss available to common stockholders, diluted:(24)(20)(15)(17)(22)(21)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(24)(13)(14)(16)(21)(20)(16)
Comprehensive loss, net of tax, attributable to parent:(24)(13)(14)(16)(21)(20)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: